Aprogen Medicines Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 27,680.66 million compared to KRW 6,657.86 million a year ago. Net loss was KRW 23,789.35 million compared to KRW 24,028.63 million a year ago. Basic loss per share from continuing operations was KRW 108 compared to KRW 141 a year ago. Diluted loss per share from continuing operations was KRW 108 compared to KRW 141 a year ago. Basic loss per share was KRW 108 compared to KRW 141 a year ago.
For the nine months, sales was KRW 1,018.61 million compared to KRW 634.58 million a year ago. Net loss was KRW 74,663.72 million compared to KRW 69,654.3 million a year ago. Basic loss per share from continuing operations was KRW 393 compared to KRW 402 a year ago. Diluted loss per share from continuing operations was KRW 393 compared to KRW 402 a year ago. Basic loss per share was KRW 393 compared to KRW 402 a year ago.